Helsinn signs distribution agreement with Immedica Pharma

Published: 24-Jan-2023

This allows for the commercialisation of two cancer supportive care products indicated for the prevention of chemotherapy-induced nausea and vomiting

Global biopharma company Helsinn Group and pharmaceutical company Immedica Pharma AB have announced that the companies have entered an exclusive long-term licence and distribution agreement.

This allows for the commercialisation of two cancer supportive care products indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV) in core European markets: AKYNZEO (Netupitant-Palonosetron fixed combination) and ALOXI (Palonosetron). Under the licence and distribution agreement Immedica will commercialise AKYNZEO in Portugal, Spain, France, Switzerland, the Netherlands, Belgium, Luxembourg and Liechtenstein, ALOXI in Switzerland, Belgium, Liechtenstein.

Anders Edvell, CEO of Immedica commented: “We are very pleased to have signed this agreement with Helsinn. Side-effects of cancer treatments have a significant impact on the quality of life of these severely ill patients. AKYNZEO and ALOXI are also an important addition to Immedica’s Oncology & Haematology portfolio.”

We look forward to working closely with Immedica in the months and years ahead

Dr Melanie Rolli, Helsinn Group CEO, commented: “This partnership will provide important treatment options for CINV across Europe. We look forward to working closely with Immedica in the months and years ahead to ensure more and more patients can access these important supportive care products.”

AKYNZEO is the first and only 5-HT and NK1 receptor antagonist fixed combination approved in Europe in adults for the prevention of acute and delayed nausea and vomiting associated with cisplatin-based highly emetogenic chemotherapy and moderately emetogenic chemotherapy.

ALOXI is approved in Europe in adults for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. ALOXI is also indicated in paediatric patients 1 month of age and older for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

Trending Articles

You may also like